Retroviral Integrase: Difference between revisions

Line 34:

|-

| [[http://www.isentress.com/raltegravir/isentress/consumer/index.jsp Raltegravir]] || Isentress || [[Merck & Co.]] || - || also known as MK-0518. Raltegravir was approved by the FDA on October 12, 2007, for use with other anti-HIV agents in the treatment of HIV infection in adults. It is the first integrase inhibitor approved by the FDA.

| [http://www.isentress.com/raltegravir/isentress/consumer/index.jsp Raltegravir] || Isentress || [[Merck & Co.]] || - || also known as MK-0518. Raltegravir was approved by the FDA on October 12, 2007, for use with other anti-HIV agents in the treatment of HIV infection in adults. It is the first integrase inhibitor approved by the FDA.

|-

| [[Elvitegravir]] || GS-9137 || [[Gilead Science]] || - || in experimental stages. Phase II studies of elvitegravir in people who are treatment experienced have been completed. Phase III studies in treatment experienced patients are ongoing. A phase II study of elvitegravir in people who have never taken antiretroviral therapy is underway. This study will also be evaluated a boosting agent in place of Norvir, currently called GS9350. Elvitegravir holds promise for HIV-positive patients who have taken other anti-HIV drugs in the past.

| [[Elvitegravir]] || GS-9137 || [[Gilead Science]] || - || in experimental stages; shares the core structure of quinolone antibiotics. Phase II studies of elvitegravir in people who are treatment experienced have been completed. Phase III studies in treatment experienced patients are ongoing. A phase II study of elvitegravir in people who have never taken antiretroviral therapy is underway. This study will also be evaluated a boosting agent in place of Norvir, currently called GS9350. Elvitegravir holds promise for HIV-positive patients who have taken other anti-HIV drugs in the past.

|-

| [[MK-2048]] || - || [[Merck & Co.]] || - || A second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP).

|-

|}

Line 45:

Line 47:

2. http://www.isentress.com/raltegravir/isentress/consumer/index.jsp

3. [http://www.thebody.com/content/art1352.html#ii HIV Antiretroviral Agents in Development]

==Further Reading==

* GEN News Highlights [http://www.genengnews.com/news/bnitem.aspx?name=74423430&nc=1 "Scientists Solve 3-D Crystal Structure of Retroviral Integrase Bound to Viral DNA"], [http://www.genengnews.com Genetic Engineering & Biotechnology News] February 1, 2010.

Retroviral Integrase: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 34: / Line 34: @@
   |-
-  | [[http://www.isentress.com/raltegravir/isentress/consumer/index.jsp Raltegravir]] || Isentress || [[Merck & Co.]] || - || also known as MK-0518. Raltegravir was approved by the FDA on October 12, 2007, for use with other anti-HIV agents in the treatment of HIV infection in adults. It is the first integrase inhibitor approved by the FDA.
+  | [http://www.isentress.com/raltegravir/isentress/consumer/index.jsp Raltegravir] || Isentress || [[Merck & Co.]] || - || also known as MK-0518. Raltegravir was approved by the FDA on October 12, 2007, for use with other anti-HIV agents in the treatment of HIV infection in adults. It is the first integrase inhibitor approved by the FDA.
   |-
-  | [[Elvitegravir]] || GS-9137 || [[Gilead Science]] || - || in experimental stages. Phase II studies of elvitegravir in people who are treatment experienced have been completed. Phase III studies in treatment experienced patients are ongoing. A phase II study of elvitegravir in people who have never taken antiretroviral therapy is underway. This study will also be evaluated a boosting agent in place of Norvir, currently called GS9350. Elvitegravir holds promise for HIV-positive patients who have taken other anti-HIV drugs in the past.
+  | [[Elvitegravir]] || GS-9137 || [[Gilead Science]] || - || in experimental stages; shares the core structure of quinolone antibiotics. Phase II studies of elvitegravir in people who are treatment experienced have been completed. Phase III studies in treatment experienced patients are ongoing. A phase II study of elvitegravir in people who have never taken antiretroviral therapy is underway. This study will also be evaluated a boosting agent in place of Norvir, currently called GS9350. Elvitegravir holds promise for HIV-positive patients who have taken other anti-HIV drugs in the past.
+ |-
+ | [[MK-2048]] || - || [[Merck & Co.]] || - || A second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP).
   |-
 |}
@@ Line 45: / Line 47: @@
 . http://www.isentress.com/raltegravir/isentress/consumer/index.jsp
+. [http://www.thebody.com/content/art1352.html#ii HIV Antiretroviral Agents in Development]
 ==Further Reading==
 * GEN News Highlights [http://www.genengnews.com/news/bnitem.aspx?name=74423430&nc=1 "Scientists Solve 3-D Crystal Structure of Retroviral Integrase Bound to Viral DNA"], [http://www.genengnews.com Genetic Engineering & Biotechnology News] February 1, 2010.